AstraZeneca Pharma India Limited

AZ Pharma India Expands Oncology Reach with $600M EGFR License to Zegfrovy

Discover how AstraZeneca Pharma India’s exclusive Zegfrovy license and new EGFR deal boost its oncology pipeline, unlock $600M upfront, and reshape cancer treatment in India.

AstraZeneca Pharma India Limited
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

14/07/2026, 08:11

4 minutes to read